Capsugel: Pulmatrix deal brings us to ‘the forefront of inhalation delivery’

Image: iStock/janulla

Capsugel has come on leaps-and-bounds since it was spun-out from Pfizer, the firm says as it inks a deal with Pulmatrix to develop inhaled therapeutics.

The capsule-maker and dosage forms services company announced this week it will exclusively manufacture clinical trial and commercial batches of novel inhaled candidates being developed by Boston, Massachusetts-based Pulmatrix, to treat pulmonary diseases with.

Capsugel will combine its spray drying process development with Pulmatrix’s iSPERSE (inhaled small particles easily respirable and emitted) platform - a small, dense and dispersible engineered particle technology which enables pulmonary delivery of drugs.

“Through this partnership, our two companies will be at the forefront of bringing unique inhalation products from conception to market to deliver better patient outcomes,” Amit Patel, President of Capsugel’s Dosage Form Solutions business told

Pulmatrix has several products in its pipeline using its tech, the lead being a clinical stage bronchodilator (PUR0200) for chronic obstructive pulmonary disease.

The work will be carried out at Capsugel’s facility in Bend, Oregon which last year completed the manufacture of its first inhalation delivery therapy for a Phase II project.

Financial details of the deal have not been divulged.

Capsugel’s transformation

Capsugel became a standalone entity in 2011 when private equity firm KKR bought Pfizer’s capsule unit for $2.4bn.

At the time of the sale, Capsugel was primarily a hard capsule provider, but since then the firm has grown both organically and through the acquisitions of Encap, Bend, and – last December – Xcelience and Powdersize.

“Our collaboration with Pulmatrix represents yet another step in this ongoing transformation,” said Patel.

“We have further strengthened our leadership in hard capsules while also significantly broadening our capabilities with a comprehensive suite of technologies and integrated solutions for designing, developing and manufacturing a wide range of finished dosage forms. 

“These broader capabilities span a range of applications, including bioavailability enhancement, modified release, micro-dosing and clinical trials services, and bio-formulation and bio-processing.”

Related News

These electron microscope images show the structures empty (left) and loaded with the cancer drug daunorubicin (right). The researchers have demonstrated for the first time that such “DNA origami” structures can be used to treat drug-resistant leukemia cells. Images by Randy Patton, courtesy of The Ohio State University.

DNA 'Trojan horse' dupes drug-resistant cancer cells

Researchers have created a dual-sided pill that attaches to the gastrointestinal tract. (Illustration: Christine Daniloff/MIT)

Pill attaches to GI tract lining for slow release


Capsugel adds European micro-dosing capacity


Bioavailability boost: Capsugel to up micronization offering at US site


Lonza confirms interest in Capsugel takeover


Lonza to buy Capsugel for $5.5bn, no site divestitures planned


Pulmatrix secures EU patent for dry powder delivery tech


Fosun and KKR extend deadline for $1.2bn Gland Pharma deal

Capsugel unwraps a couple of dosage form solution bolt-ons - photo karandaev/iStock

Capsugel double acquisition bolsters dosage forms business

The facility in Ediburgh, Scotland was acquired when Capsugel bought Encap in 2013

Capsugel expanding Encap plant on rising HPAPI demand

Capsugel is formulating biotherapeutics to be delivered into the lungs

Capsugel focusing on inhaled biotherapeutics from Bend facility

Three Capsugel plants have seen recent expansions

Capsugel expands manufacturing capacity at three FDF plants

New DFS Unit Built on Technology, R&D and Manufacturing, says Capsugel

New DFS Unit Built on Technology, R&D and Manufacturing, says Capsugel

Related Products

See more related products